BRAF V600E is a driver mutation observed in approximately 3% of NSCLC patients, and such patients may be treated with a combination of trametinib (a MEK inhibitor) and dabrafenib (a BRAF inhibitor) [104]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.